Richter et al. showed that MYC + DLBCL patients, with or without BCL2 and/or BCL6 rearrangements, were overrepresented (6/25 vs 21/241) in the I-PET positive group, using the delta SUV response criterion, compared to the I-PET negative group [22]. This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.